SCHEMBL17048607

SCHEMBL17048607

CC[Si](CC)(CC)OC(CNCc1cc(F)cc(F)c1)c1c(Cl)cccc1OC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.36
KMT2A Q03164 5/20 0.36
MEN1 O00255 4/20 0.36
P2RX7 Q99572 2/20 0.36
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
HTR1A P08908 3/20 0.35
HTR1D P28221 3/20 0.35
HTR2A P28223 3/20 0.35
HTR2C P28335 3/20 0.35
HTR7 P34969 3/20 0.35
HTR2B P41595 3/20 0.35
HTR5A P47898 3/20 0.35
HTR6 P50406 3/20 0.35
HTR1B P28222 2/20 0.35
BACE1 P56817 3/20 0.35
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17056942 0.92 BACE1 (0.37) KMT2AMEN1P2RX7BACE1SMN1; SMN2
SCHEMBL17117938 0.91 TMEM97 (0.39) POLBKMT2AMEN1P2RX7TMEM97
SCHEMBL17117996 0.87 POLB (0.38) POLBKMT2AMEN1P2RX7TMEM97
SCHEMBL17117957 0.85 TMEM97 (0.36) KMT2AMEN1P2RX7TMEM97SIGMAR1
SCHEMBL17056845 0.84 TMEM97 (0.35) TMEM97SIGMAR1
SCHEMBL17056960 0.84 TMEM97 (0.35) POLBKMT2AMEN1TMEM97SIGMAR1
SCHEMBL17117950 0.84 POLB (0.35) POLBKMT2AMEN1P2RX7TMEM97
SCHEMBL17057046 0.82 TMEM97 (0.34) POLBTMEM97SIGMAR1
SCHEMBL17118083 0.81 TMEM97 (0.41) POLBKMT2AMEN1TMEM97SIGMAR1
SCHEMBL17056937 0.81 KCNH2 (0.33) POLBKMT2AMEN1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3110810-B1 PYRAZOLE AMIDE DERIVATIVE TEIJIN PHARMA LTD (JP) 2018-05-02 EP disclosed
EP-3110810-B1 PYRAZOLE AMIDE DERIVATIVE TEIJIN PHARMA LTD (JP) 2018-05-02 EP disclosed
EP-3110810-A1 PYRAZOLE AMIDE DERIVATIVE Teijin Pharma Limited (JP) 2017-01-04 EP disclosed
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US disclosed
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US disclosed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US disclosed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US disclosed
WO-2015129926-A1 PYRAZOLE AMIDE DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2015-09-03 WO disclosed
WO-2015129926-A1 PYRAZOLE AMIDE DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2015-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266824-A1 Pyrazole Amide Derivative RORC, RORB, RORA POLB 4102/4885KMT2A 1635/4885MEN1 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.